Article

Anecortave acetate proving helpful for inhibiting CNV growth

Anaheim, CA-Anecortave acetate (Retaane, Alcon), a potent angiostatic agent, has been shown to be safe and superior to placebo in reducing loss of vision from baseline, avoiding severe vision loss, and inhibiting the growth of CNV membranes in patients with age-related macular degeneration (AMD), according to Jason S. Slakter, MD, who spoke during the American Academy of Ophthalmology annual meeting.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.